We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
SPDR Gold MiniShares Trust
GLDM
$27.5B
| $560K | ﹤0.01% |
+6,561
| New | +$539K |
|
877
Norwegian Cruise Line
NCLH
$9.53B
| $557K | ﹤0.01% |
24,964
| – | – |
|
878
ATS Corp
ATS
$2.57B
| $551K | ﹤0.01% |
20,007
+1,412
| +8% | +$37.7K |
|
|
ELME
879
Elme Communities
ELME
$145M
| $549K | ﹤0.01% |
31,549
+963
| +3% | +$16.3K |
|
|
ALEX
880
DELISTED
Alexander & Baldwin
ALEX
| $541K | ﹤0.01% |
26,207
+1,214
| +5% | +$21.1K |
|
|
NTST
881
NETSTREIT Corp
NTST
$2.13B
| $532K | ﹤0.01% |
30,147
-1,831
| -6% | -$33.3K |
|
|
GTY
882
Getty Realty Corp
GTY
$2.16B
| $529K | ﹤0.01% |
19,336
+2,405
| +14% | +$66.5K |
|
883
Millicom
TIGO
$15.8B
| $521K | ﹤0.01% |
9,390
-529,698
| -98% | -$26.7M |
|
884
Credo Technology Group
CRDO
$33.1B
| $517K | ﹤0.01% |
+3,593
| New | +$553K |
|
885
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
$19.1B
| $498K | ﹤0.01% |
10,074
+2,506
| +33% | +$125K |
|
886
Paycom
PAYC
$7.88B
| $495K | ﹤0.01% |
3,104
-7,161
| -70% | -$1.27M |
|
|
XHR
887
Xenia Hotels & Resorts
XHR
$2.01B
| $482K | ﹤0.01% |
34,065
-1,367
| -4% | -$18.6K |
|
888
Pebblebrook Hotel Trust
PEB
$2.18B
| $477K | ﹤0.01% |
42,145
+813
| +2% | +$8.95K |
|
889
Aecom
ACM
$9.46B
| $476K | ﹤0.01% |
4,988
-5,161
| -51% | -$607K |
|
890
Conagra Brands
CAG
$7.42B
| $475K | ﹤0.01% |
27,436
-13,781
| -33% | -$245K |
|
891
Erie Indemnity
ERIE
$13B
| $466K | ﹤0.01% |
1,626
| – | – |
|
892
Lufax Holding
LU
$1.33B
| $465K | ﹤0.01% |
181,758
-1,363
| -0.7% | -$4.03K |
|
|
SILA
893
DELISTED
Sila Realty Trust
SILA
| $465K | ﹤0.01% |
19,947
+261
| +1% | +$6.14K |
|
894
MGM Resorts International
MGM
$11.7B
| $463K | ﹤0.01% |
12,702
| – | – |
|
895
Generac Holdings
GNRC
$11.5B
| $461K | ﹤0.01% |
3,384
| – | – |
|
|
UMH
896
UMH Properties
UMH
$1.34B
| $457K | ﹤0.01% |
28,732
+1,935
| +7% | +$29.1K |
|
897
Molson Coors Class B
TAP
$8.02B
| $456K | ﹤0.01% |
9,775
-62,859
| -87% | -$2.9M |
|
898
XP
XP
$8.43B
| $443K | ﹤0.01% |
27,076
+1,874
| +7% | +$33K |
|
899
Henry Schein
HSIC
$9.78B
| $441K | ﹤0.01% |
5,837
| – | – |
|
900
The Mosaic Company
MOS
$7.19B
| $434K | ﹤0.01% |
18,034
-14,675
| -45% | -$395K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.